Business Context and Reporting Period
MIRA Pharmaceuticals, Inc. (MIRA), an emerging growth company incorporated in Florida, filed this Form 8-K on June 17, 2026. The report discloses a significant corporate development regarding its proprietary drug candidate, Ketamir-2, an oral NMDA receptor modulator intended for the treatment of chemotherapy-induced peripheral neuropathy (CIPN).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This Form 8-K is a current report focused on a specific regulatory event and does not contain financial statements or performance metrics.
Material Changes
The material change reported is the submission of a Phase 2a clinical trial protocol to the U.S. Food and Drug Administration (FDA) for Ketamir-2. The Company received an acknowledgment of receipt from the FDA confirming the acceptance of the submission for Protocol Mira-002.
Guidance, Outlook, and Risks
Management commentary is limited to the announcement of the FDA submission and the receipt of the acknowledgment. The filing does not provide specific financial guidance, future outlook projections, or a detailed discussion of risks and contingencies beyond the standard regulatory disclosure language. The information furnished in Item 7.01 is not deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the status of the FDA review for Protocol Mira-002 following the acknowledgment of receipt.
- Review the attached press release (Exhibit 99.1) for detailed clinical trial design and objectives.
- Confirm the Company's cash runway and funding status, as this filing does not disclose current liquidity levels.
- Monitor for future filings regarding the initiation of the Phase 2a trial or any FDA feedback on the protocol.